New pill may help cancer patients avoid chemo delays due to low platelets

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key eligibility criteria: 1. Female, aged 18-75 years (inclusive). 2. Histopathologically or cytologically confirmed ovarian, cervical, endometrial, or other gynecologic malignancy. 3. Thrombocytopenia (platelet count \< 75 × 10⁹/L) attributable to anti-cancer therapy, with ≥ 2 further treatment cycles planned. 4. ECOG performance status 0-1. 5. Estimated life expectancy ≥ 12 weeks. 6. Women of child-bearing potential must have a negative serum pregnancy test within 7 days before first dose, not be breastfeeding, and agree to use effective contraception from study entry through 7 days after the last dose. 7. Able to provide written informed consent and comply with study procedures. Exclusion criteria: 1. Pregnant or lactating women. 2. Unable to understand the study nature or give informed consent. 3. History of any arterial or venous thrombosis (stroke, TIA, MI, DVT, PE) or clinical/laboratory evidence of thrombophilia. 4. Cardiac disease within 3 months before screening: NYHA class III/IV heart failure, symptomatic arrhythmia requiring therapy, MI, arrhythmias increasing thrombotic risk (e.g., atrial fibrillation), or QTc prolongation. 5. Thrombocytopenia not related to anti-cancer therapy, active severe bleeding, or refractory persistent thrombocytopenia. 6. Significant hepatic impairment: * No liver metastases: ALT/AST \> 3 × ULN or TBL \> 3 × ULN * Liver metastases: ALT/AST ≥ 5 × ULN or TBL ≥ 5 × ULN 7. Known or suspected hypersensitivity/intolerance to TPO-receptor agonists or hetrombopag excipients. 8. Concomitant use of agents that may affect platelet count (e.g., Chinese herbal medicines, other thrombopoietic agents, antiplatelet drugs). 9. Receipt within 1 month before screening of TPO-RAs (eltrombopag, romiplostim, etc.), rhTPO, or rhIL-11. 10. Platelet transfusion within 3 days before randomisation/first dose. 11. Any condition that, in the investigator's opinion, renders the patient unsuitable for the study.